Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference

Rhea-AI Summary

Gain Therapeutics, Inc. (Nasdaq: GANX) announced its participation in the 2022 BTIG Biotechnology Conference on August 9 at 12 p.m. ET. The event will take place in New York City on August 8-9. The company will engage in a fireside chat and host investor meetings. Gain's unique computational platform, SEE-Tx®, identifies novel allosteric binding sites to revolutionize drug discovery, targeting diseases like Parkinson’s. Their work has garnered funding from notable organizations, including The Michael J. Fox Foundation.

BETHESDA, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that members of management will participate in a fireside chat at the 2022 BTIG Biotechnology Conference on Tuesday, August 9 at 12 p.m. ET and host investor meetings. The hybrid conference will take place August 8-9 in New York City.

To listen to the live event or schedule meetings with management, please contact your BTIG representative.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com.

Investor & Media Contact:

Noor Pahlavi
Argot Partners
(212) 600-1902
Gain@argotpartners.com

FAQ

What is Gain Therapeutics, Inc. participating in on August 9, 2022?

Gain Therapeutics, Inc. will participate in the 2022 BTIG Biotechnology Conference on August 9 at 12 p.m. ET.

What is the main focus of Gain Therapeutics' drug discovery?

Gain Therapeutics focuses on transforming drug discovery through its proprietary platform, SEE-Tx®, identifying novel allosteric binding sites.

Where is the 2022 BTIG Biotechnology Conference being held?

The conference will take place in New York City on August 8-9, 2022.

What diseases does Gain Therapeutics' pipeline target?

Gain Therapeutics targets neurodegenerative diseases, lysosomal storage disorders, metabolic diseases, and oncology.

What support has Gain Therapeutics' lead program in Parkinson’s disease received?

Gain’s lead program in Parkinson’s disease has received funding from The Michael J. Fox Foundation and other organizations.